28.00
8.78%
2.26
After Hours:
28.29
0.29
+1.04%
Denali Therapeutics Inc stock is traded at $28.00, with a volume of 867.08K.
It is up +8.78% in the last 24 hours and up +3.40% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$25.74
Open:
$25.59
24h Volume:
867.08K
Relative Volume:
0.94
Market Cap:
$4.01B
Revenue:
$340.81M
Net Income/Loss:
$-145.22M
P/E Ratio:
-25.69
EPS:
-1.09
Net Cash Flow:
$-370.93M
1W Performance:
-2.20%
1M Performance:
+3.40%
6M Performance:
+46.06%
1Y Performance:
+30.35%
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8548
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-13-23 | Initiated | Citigroup | Buy |
Nov-20-23 | Resumed | JP Morgan | Overweight |
Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
Sep-06-23 | Initiated | B. Riley Securities | Buy |
Jan-30-23 | Initiated | SVB Securities | Outperform |
Dec-05-22 | Initiated | Cowen | Outperform |
Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
Nov-02-22 | Initiated | BofA Securities | Buy |
Jun-23-22 | Initiated | Berenberg | Buy |
Dec-10-21 | Resumed | Raymond James | Mkt Perform |
Sep-21-21 | Initiated | Oppenheimer | Outperform |
Sep-01-21 | Initiated | SMBC Nikko | Outperform |
May-18-21 | Initiated | UBS | Buy |
Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
Sep-14-20 | Resumed | JP Morgan | Overweight |
Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
Feb-24-20 | Initiated | Jefferies | Buy |
Feb-19-20 | Initiated | Stifel | Hold |
Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
Sep-26-19 | Initiated | Wedbush | Neutral |
Sep-13-19 | Initiated | Nomura | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jun-26-19 | Initiated | H.C. Wainwright | Buy |
Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
Nov-12-18 | Initiated | Janney | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Jan-02-18 | Initiated | Evercore ISI | Outperform |
Jan-02-18 | Initiated | Goldman | Neutral |
Jan-02-18 | Initiated | JP Morgan | Overweight |
Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Denali Therapeutics (NASDAQ:DNLI) Trading Up 6.4%Still a Buy? - MarketBeat
Sanofi, Denali face trial setback for neuro drug (NASDAQ:DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Price Target Lowered to $28.00 at JPMorgan Chase & Co. - MarketBeat
Denali Therapeutics Inc [DNLI] Director makes an insider purchase of 30,000 shares worth 0.87 million. - Knox Daily
Denali Therapeutics Inc (DNLI)’s stock price in review: A technical analysis - US Post News
8 Stocks Jeff Bezos is Buying - Insider Monkey
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug - Reuters
Denali Therapeutics halts multiple sclerosis study By Investing.com - Investing.com UK
Denali Therapeutics' (DNLI) "Market Perform" Rating Reiterated at Raymond James - MarketBeat
How the (DNLI) price action is used to our Advantage - Stock Traders Daily
Analyzing the Impact of Earnings Reports on Denali Therapeutics Inc Inc. (DNLI) Price Performance - The InvestChronicle
The Potential Rise in the Price of Denali Therapeutics Inc (DNLI) following insiders activity - Knox Daily
Denali Therapeutics Inc’s Market Journey: Closing Weak at 26.60, Down -7.09 - The Dwinnex
The Manufacturers Life Insurance Company Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownTime to Sell? - MarketBeat
Denali Therapeutics (NASDAQ:DNLI) Rating Lowered to Neutral at Cantor Fitzgerald - MarketBeat
Algert Global LLC Lowers Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Squarepoint Ops LLC Has $2.87 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Steve E. Krognes Sells 30,000 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) Stock - MarketBeat
In the Green: Denali Therapeutics Inc (DNLI) Closes at 28.67, Up/Down -1.58 from Previous Day - The Dwinnex
Denali Therapeutics Inc. (NASDAQ:DNLI) Stock Holdings Lifted by Dimensional Fund Advisors LP - MarketBeat
Brokerages Set Denali Therapeutics Inc. (NASDAQ:DNLI) Target Price at $38.33 - MarketBeat
Thrivent Financial for Lutherans Grows Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
27,014 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Fred Alger Management LLC - MarketBeat
Point72 Asset Management L.P. Takes $24.45 Million Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Marshall Wace LLP Boosts Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Profund Advisors LLC Sells 39,101 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Ensign Peak Advisors Inc Sells 298,541 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - MarketBeat
Denison Mines stock upgraded by BMO analyst citing attractive P/NPV ratio and strong balance sheet - Investing.com India
Danimer Scientific awarded $1.36 million by DoD - Investing.com India
Denison Mines Corp. - Baystreet.ca
This trade activity should not be overlooked: Denali Therapeutics Inc (DNLI) - SETE News
Denison Mines (NYSEAMERICAN:DNN) Trading Up 5% - Defense World
Hood River Capital Management LLC Has $50.28 Million Stock Holdings in Denison Mines Corp. (NYSEAMERICAN:DNN) - Defense World
Integral Health Asset Management LLC Acquires New Stake in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Danimer Scientific Inc (DNMR Stock: A Sea of Opportunity - The InvestChronicle
Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by American Century Companies Inc. - MarketBeat
State of New Jersey Common Pension Fund D Trims Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Danimer Scientific, Inc. (NYSE:DNMR) Short Interest Down 5.1% in August - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - Kilgore News Herald
(DNLI) On The My Stocks Page - Stock Traders Daily
Denali Therapeutics (NASDAQ:DNLI) Sets New 52-Week High at $31.00 - MarketBeat
Denali Therapeutics director sells $30,600 in company stock - Investing.com India
Denali Therapeutics director sells $30,600 in company stock By Investing.com - Investing.com Canada
Denali Therapeutics director sells $30,600 in company stock - Investing.com
Denali Therapeutics director sells $30,600 in company stock By Investing.com - Investing.com UK
Brokers Issue Forecasts for Denali Therapeutics Inc.'s FY2025 Earnings (NASDAQ:DNLI) - MarketBeat
Rhumbline Advisers Acquires 22,900 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Strength Seen in Denali Therapeutics (DNLI): Can Its 10.1% Jump Turn into More Strength? - Yahoo Finance
ClariVest Asset Management LLC Has $533,000 Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - MarketBeat
Denali Therapeutics Insiders Sell US$1.8m Of Stock, Possibly Signalling Caution - Simply Wall St
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):